A Case of Refractory Pediatric Crohn's Disease with a Successful Treatment by Infliximab Therapy.
- Author:
Sang Hoon PARK
1
;
Yoon Tae JEEN
;
Hwang Rae CHUN
;
Dong Il KIM
;
Chang Won BAECK
;
Yong Sik KIM
;
Hoon Jai CHUN
;
Hong Sik LEE
;
Soon Ho UM
;
Jai Hyun CHOI
;
Chang Duck KIM
;
Ho Sang RYU
;
Jin Hai HYUN
Author Information
1. Department of Internal Medicine, Institute of Digestive Disease and Nutrition, Korea University College of Medicine, Seoul, Korea. ytjeen@korea.ac.kr
- Publication Type:Case Report ; English Abstract
- Keywords:
Crohn's disease;
Pediatrics;
Infliximab
- MeSH:
Antibodies, Monoclonal/*administration & dosage;
Child;
Crohn Disease/*drug therapy;
Drug Administration Schedule;
English Abstract;
Gastrointestinal Agents/*administration & dosage;
Humans;
Infusions, Intravenous;
Male
- From:The Korean Journal of Gastroenterology
2005;46(4):297-301
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.
